Quetiapine

Generic Name: Quetiapine

Brand Names: Seroquel

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₃O_₂S

CAS Number: 111974-69-7

Unique Ingredient Identifier: BGL0JSY5SI

Background: Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.

Indication: Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.

Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.

Associated Conditions: Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Clinical Trials

Antipsychotic to Treat Psychosis Syndrome

Not Applicable

Conditions: Psychotic Disorders

Interventions: Drug: Quetiapine
Drug: risperidone
Drug: olanzapine
Drug: Aripiprazole

First Posted Date: 2014-05-14

Last Posted Date: 2014-05-14

Lead Sponsor: Central South University

Target Recruit Count: 300

Registration Number: NCT02137616

Locations: 🇨🇳
the Second Xiangya Hospital, Changsha, Hunan, China

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Quetiapine XR (extended release)

First Posted Date: 2014-05-07

Last Posted Date: 2014-05-07

Lead Sponsor: University of Calgary

Target Recruit Count: 57

Registration Number: NCT02132286

Locations: 🇨🇦
University of Calgary: Foothills medical centre, Calgary, Alberta, Canada

Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine

Phase 1

Completed

Conditions: Dementia
Delirium

Interventions: Drug: Quetiapine 25 mg gel applied topically
Drug: Quetiapine 25 mg tablet by mouth
Drug: Quetiapine 25 mg rectal suppository

First Posted Date: 2014-05-06

Last Posted Date: 2017-04-25

Lead Sponsor: Mayo Clinic

Target Recruit Count: 10

Registration Number: NCT02131545

Locations: 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

Safety and Tolerability of Quetiapine in Multiple Sclerosis

Phase 1

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Extended-release quetiapine fumarate

First Posted Date: 2014-03-14

Last Posted Date: 2019-10-09

Lead Sponsor: University of Calgary

Target Recruit Count: 14

Registration Number: NCT02087631

Locations: 🇨🇦
MS Clinic, Foothills Medical Centre, Calgary, Alberta, Canada

Efficacy of Quetiapine for Pediatric Delirium

Phase 1

Terminated

Conditions: Delirium

Interventions: Drug: quetiapine
Other: Placebo

First Posted Date: 2014-02-05

Last Posted Date: 2017-12-13

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 6

Registration Number: NCT02056171

Locations: 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
NY Prebyterian Hospital/Weill Cornell Medical Center, New York, New York, United States